Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study
Journal article published in 2018 by
F. Cavalli,
J. Jin,
H. Pylypenko,
G. Verhoef,
N. Siritanaratkul,
J. Drach,
M. Raderer,
J. Mayer,
J. Pereira 
,
G. Tumyan,
R. Okamoto,
S. Nakahara,
P. Hu,
C. Appiani,
S. Nemat
and other authors.
,
G. Tumyan,
R. Okamoto,
S. Nakahara,
P. Hu,
C. Appiani,
S. Nemat
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 